US Bancorp
CUE icon

US Bancorp’s Cue Biopharma CUE Stock Holding History

US Bancorp’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.3K Buy
+400
New +$11.9K ﹤0.01% 3472

Other funds holding CUE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Robertson Stephens Wealth Management
Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Gleason Group
Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Golden State Wealth Management
Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

US Bancorp's CUE Position: Q3 2026 in Review

US Bancorp opened a new position in Cue Biopharma (CUE) in Q3 2026: 400 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #3472 among its holdings.

12 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

  • US Bancorp held 400 shares of Cue Biopharma worth $10.3K as of Q3 2026.
  • Cue Biopharma was a new US Bancorp position in Q3 2026.
  • Cue Biopharma made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #3472 holding.
  • 12 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.